The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis

Respiratory Research

Volumn 19, Issue 1, 2018, Pages

  Usmani, Omar S ^a   Biddiscombe, Martyn F ^a,b   Yang, Shuying ^c   Meah, Sally ^a   Oballa, Eunice ^c   Simpson, Juliet K ^c   Fahy, William A ^c   Marshall, Richard P ^c   Lukey, Pauline T ^c   Maher, Toby M ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Gamma scintigraphy; Idiopathic pulmonary fibrosis (IPF); Inhaled drug delivery

Indexed keywords

SALBUTAMOL; TECHNETIUM 99M; BRONCHODILATING AGENT;

ADULT; AEROSOL; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISPERSION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG PENETRATION; FEMALE; FIBROSING ALVEOLITIS; HUMAN; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NEBULIZATION; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PHASE 1 CLINICAL TRIAL; PROCEDURES; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ALBUTEROL; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED;

EID: 85041412818     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-018-0732-0     Document Type: Article

References (42)

1. Arbat S, et al. Study of factors affecting mortality in ILD cases over 2 years. Eur Respir J. 2016;48(suppl 60)
2. Hutchinson J, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795-806.
3. Kärkkäinen M, et al. Course of disease and cause of death in patients with idiopathic pulmonary fibrosis in eastern Finland. Eur Respir J. 2015;46(suppl 59)
4. Rogliani P, et al. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Pulm Pharmacol Ther. 2016;40:95-103.
5. Lavorini F, Fontana GA, Usmani OS. New inhaler devices-the good, the bad and the ugly. Respiration. 2014;88(1):3-15.
6. Okuda R, et al. Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis: a prospective, single-arm study. Respir Investig. 2016;54(3):156-61.
7. Fusiak T, Smaldone GC, Condos R. Pulmonary fibrosis treated with inhaled interferon-gamma (IFN-γ). J Aerosol Med Pulm Drug Deliv. 2015;28(5):406-10.
8. Markart P, et al. Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2010;23(3):161-72.
9. Strickland NH, et al. Cause of regional ventilation-perfusion mismatching in patients with idiopathic pulmonary fibrosis: a combined CT and scintigraphic study. AJR Am J Roentgenol. 1993;161(4):719-25.
10. Ogawa Y, et al. Regional ventilation-perfusion mismatch in interstitial pneumonia correlation between scintigraphy and CT. Clin Nucl Med. 1997;22(3):166-71.
11. Suga K, et al. Characteristic crescentic subpleural lung zones with high ventilation (V)/perfusion (Q) ratios in interstitial pneumonia on V/Q quotient SPECT. Nucl Med Commun. 2009;30(11):881-9.
12. Hirani N, et al. TD139, A Novel Inhaled Galectin-3 Inhibitor for The Treatment of Idiopathic Pulmonary Fibrosis (IPF). Results from The First in (IPF) Patients Study. QJM. 2016;109(suppl_1):S16-S16.
13. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497-504.
14. Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation [see comments]. Br J Clin Pharmacol. 1992;34(4):311-5.
15. Hindle M, Newton D, Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax. 1993;48(6):607-10.
16. Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
17. Assayag D, et al. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med. 2015;109(8):1058-62.
18. Usmani OS, et al. Characterization of the generation of radiolabeled monodisperse albuterol particles using the spinning-top aerosol generator. J Nucl Med. 2004;45(1):69-73.
19. Biddiscombe MF, Usmani OS, Barnes PJ. A system for the production and delivery of monodisperse salbutamol aerosols to the lungs. Int J Pharm. 2003;254(2):243-53.
20. Newman S, et al. Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv. 2012;25(S1):S-10-28.
21. Du X-L, et al. Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. Acta Pharmacol Sin. 2002;23(7):663-6.
22. Elers J, et al. Blood and urinary concentrations of salbutamol in asthmatic subjects. Med Sci Sports Exerc. 2010;42(2):244-9.
23. Horan GS, et al. Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177(1):56-65.
24. Lipson KE, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(1):1.
25. Edwards CD, et al. Development of a novel quantitative structure-activity relationship model to accurately predict pulmonary absorption and replace routine use of the isolated perfused respiring rat lung model. Pharm Res. 2016;33(11):2604-16.
26. Bäckman P, et al. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Therap. 2014;95(5):509-20.
27. Patton JS, et al. The particle has landed--characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 2):S71-87.
28. Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24(135):58-64.
29. Biddiscombe MF, et al. Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition. J Aerosol Med Pulm Drug Deliv. 2011;24(3):165-73.
30. Mukhopadhyay S, et al. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med. 1994;88(3):203-11.
31. Fairfax A, et al. Pulmonary disorders associated with Sjögren's syndrome. QJM. 1981;50(3):279-95.
32. Bando M, et al. Long-term efficacy of inhaled N-acetylcysteine in patients with idiopathic pulmonary fibrosis. Intern Med. 2010;49(21):2289-96.
33. Homma S, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology. 2012;17(3):467-77.
34. Muramatsu Y, et al. Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis. Respir Investig. 2016;54(3):170-8.
35. Diaz KT, et al. Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2012;25(2):79-87.
36. Skaria SD, et al. Inhaled interferon and diffusion capacity in idiopathic pulmonary fibrosis (IPF). Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(1):37-42.
37. Hochhaus G, Möllmann H. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992;30(9):342-62.
38. Newman SP, et al. Deposition of pressurised aerosols in the human respiratory tract. Thorax. 1981;36(1):52-5.
39. Hindle M, Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Thorax. 1994;49(6):549-53.
40. Hindle M, et al. Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler. Br J Clin Pharmacol. 1997;43(3):336-8.
41. Chege J, Chrystyn H. Volumatic usage: some generic salbutamol metered dose inhalers can be used. Thorax. 1994;49(11):1162-3.
42. Silkstone V, et al. Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged. Br J Clin Pharmacol. 2000;50(3):281-4.